MOR106 is an investigational human monoclonal IL-17C antibody for the treatment of inflammatory diseases and furthermore our first Ylanthia antibody in the clinical development

MOR106 is an investigational human monoclonal antibody directed against IL-17C in clinical development worldwide. MOR106 is also the first antibody from MorphoSys’s Ylanthia platform to enter clinical development. In preclinical models, IL-17C has been shown to play an important role in inflammatory skin disorders. 


Proposed Mode of Action

We believe MOR106 is the first antibody in clinical development worldwide targeting the IL-17C antigen. MOR106 is thought to bind to the cytokine IL-17C, a novel target, which is up-regulated in inflammatory skin disorders such as psoriasis and atopic dermatitis. Based on findings from pre-clinical models, IL-17C plays an important and pro-inflammatory role in these skin disorders. Importantly, IL-17C has been shown to be distinct from other members of the IL-17 cytokine family in its biological function, as it is produced by different cell types, predominantly epithelial cells. Results in rodent inflammatory skin models support clinical development of MOR106.
Binding of IL-17C to its receptor consisting of the subunits IL-17-RA and IL-17-RE is assumed to trigger an inflammatory cascade that plays a promoting role in skin diseases. By potentially binding to IL-17C, MOR106 is thought to block the binding of the cytokine to its receptor, thus neutralizing the cytokine’s biological activity.

The figure depicts the suggested mechanism of action of MOR106

Clinical Studies

MOR106 was jointly discovered by us and Galapagos. In July 2018, we and Galapagos entered into an exclusive worldwide development and commercialization collaboration with Novartis with respect to MOR106. The antibody has been investigated in four clinical studies in patients with moderate to severe atopic dermatitis: Two phase 2 studies IGUANA and GECKO, as well as a phase 1 bridging study for subcutaneous formulation and a Japanese ethno-bridging study. On October 2019, we, Galapagos NV and Novartis Pharma AG announced the end of the clinical development program of MOR106 in atopic dermatitis. The joint decision of all three involved parties, us, Galapagos NV and Novartis Pharma AG, was based on an interim analysis for futility that was performed in the phase 2 IGUANA trial. The analysis detected a low probability to meet the primary endpoint of the study, defined as the percentage change in the eczema area and severity index (EASI) score. The decision was based on a lack of efficacy and not on safety concerns. All studies in atopic dermatitis were ended. The parties will explore the future strategy with MOR106 .  

Currently active clinical trials



MOR106 was generated in a collaboration between us and Galapagos. In July 2018, we and Galapagos entered into a worldwide, exclusive agreement with Novartis Pharma AG covering the development and commercialization of the joint program MOR106. Novartis exclusively holds all rights for commercialization of any products resulting from the agreement. After the current development program in atopic dermatitis has been stopped, the parties will explore the future strategy with MOR106.